Friday, March 15, 2019 1:08:36 PM
The following is bullshit.
They never got to the pre FDA testing stage.
Therapy Cells, Inc. develops and commercializes a technology for tendon repair for the human market. The company has market cap of $584,496. The Company’s technology is used for tissue transplantation to aid in the repair and regeneration of damaged, diseased, torn, or ruptured musculoskeletal cells and organs in the human, as well as to grow pancreatic cells, for treatment of diabetes, cardiac cells for the treatment of heart disease, and other cell types from various other tissues. It currently has negative earnings. The firm was formerly known as Diamond Information Institute, Inc. and changed its name to Therapy Cells, Inc. in May 2011.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM